A high risk of osteosarcoma in individuals who are homozygous for the p.D104N in endostatin

[1]  Wenguo Jiang,et al.  Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis , 2013, BMC Cancer.

[2]  X. Yu,et al.  Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis , 2013, Tumor Biology.

[3]  F. Costa,et al.  A high risk of occurrence of sporadic breast cancer in individuals with the 104NN polymorphism of the COL18A1 gene , 2006, Breast Cancer Research and Treatment.

[4]  G. Letson,et al.  Orthopedic surgery options for the treatment of primary osteosarcoma. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[5]  T Visakorpi,et al.  Molecular genetics of prostate cancer. , 2001, Annals of medicine.

[6]  A. Camargo,et al.  A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. , 2001, Cancer research.

[7]  T. Yamashita,et al.  Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin , 2007, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[8]  Misa Nakamura,et al.  Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer , 2005, Breast Cancer Research and Treatment.

[9]  A. Lacy,et al.  PROSPECTIVE STUDY , 2014 .

[10]  Hyunjoong Kim,et al.  Functional Analysis I , 2017 .

[11]  H. Ishwaran,et al.  Lung metastasis genes couple breast tumor size and metastatic spread , 2007, Proceedings of the National Academy of Sciences.

[12]  S. Cross,et al.  Endostatin gene variation and protein levels in breast cancer susceptibility and severity , 2007, BMC Cancer.

[13]  W. Bi,et al.  Effects of endostar combined multidrug chemotherapy in osteosarcoma. , 2013, Bone.

[14]  Su Dan,et al.  Pharmacogenetic Angiogenesis Profiling for First-Line Chemotherapy in Patients With Advanced Gastric Cancer , 2013, Cancer investigation.

[15]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[16]  M. Mison,et al.  Osteosarcoma , 1985, The Lancet.

[17]  Peter F. M. Choong,et al.  The Molecular Pathogenesis of Osteosarcoma: A Review , 2011, Sarcoma.

[18]  C. Lima,et al.  A polymorphism in the angiogenesis inhibitor, endostatin, in lung cancer susceptibility. , 2008, Lung cancer.

[19]  B. Mendonca,et al.  Genotype analysis of the human endostatin variant p.D104N in benign and malignant adrenocortical tumors , 2012, Clinics.

[20]  Su-zhan Zhang,et al.  Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft. , 2011, Cancer letters.

[21]  P. Kantoff,et al.  Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study , 2009, International journal of cancer.

[22]  G. Haas,et al.  Association of MnSOD AA Genotype with the Progression of Prostate Cancer , 2015, PloS one.

[23]  M. Gondo,et al.  Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene , 1999, Nature Biotechnology.

[24]  P. Kantoff,et al.  Genotyping and functional analysis of the D104N variant of human endostatin , 2004, Cancer biology & therapy.

[25]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[26]  M. Boffa,et al.  Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. , 2008, Blood.

[27]  F. Costa,et al.  A polymorphism in the angiogenesis inhibitor, endostatin, in multiple myeloma. , 2003, Leukemia research.

[28]  T. Serikawa,et al.  Functional polymorphisms in inbred rat strains and their allele frequencies in commercially available outbred stocks. , 2008, Physiological genomics.

[29]  D. Tang,et al.  HMGB1 promotes drug resistance in osteosarcoma. , 2012, Cancer research.

[30]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[31]  Yong-Koo Park,et al.  Anti‐angiogenic factor endostatin in osteosarcoma , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[32]  K. Alitalo,et al.  Endostatin signaling and regulation of endothelial cell-matrix interactions. , 2005, Advances in cancer research.

[33]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.